EPS for Adamas Pharmaceuticals, Inc. (ADMS) Expected At $-1.44

July 14, 2018 - By Ann Prendergast

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Logo

Analysts expect Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to report $-1.44 EPS on August, 14.They anticipate $0.51 EPS change or 54.84 % from last quarter’s $-0.93 EPS. After having $-1.35 EPS previously, Adamas Pharmaceuticals, Inc.’s analysts see 6.67 % EPS growth. The stock increased 2.73% or $0.72 during the last trading session, reaching $27.06. About 491,901 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 88.75% since July 14, 2017 and is uptrending. It has outperformed by 76.18% the S&P500.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Among 6 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamas Pharmaceuticals had 11 analyst reports since January 23, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, January 23 by Mizuho. On Thursday, February 22 the stock rating was maintained by Piper Jaffray with “Buy”. Mizuho maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating on Tuesday, February 20. Mizuho has “Buy” rating and $48.0 target. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) earned “Buy” rating by Mizuho on Friday, March 9. The stock has “Buy” rating by Needham on Friday, February 23. On Wednesday, April 4 the stock rating was initiated by Leerink Swann with “Buy”. The firm has “Buy” rating by Mizuho given on Thursday, April 19. Mizuho maintained the stock with “Buy” rating in Friday, June 22 report. The firm has “Buy” rating by Piper Jaffray given on Tuesday, January 30. The firm earned “Buy” rating on Tuesday, February 20 by Evercore.

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company has market cap of $730.14 million. The company's product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It currently has negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

More news for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) were recently published by: Globenewswire.com, which released: “Adamas Announces New Employment Inducement Grant” on July 09, 2018. Nasdaq.com‘s article titled: “Adamas Presents New Data Analysis Demonstrating that GOCOVRIâ„¢ Reduces Transitions between Dyskinesia and …” and published on June 22, 2018 is yet another important article.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: